Differences

This shows you the differences between two versions of the page.

--- philip_krause [2023/03/12 06:59]
liam
+++ philip_krause [2023/04/10 02:56] (current)
liam
@@ Line 7: / Line 7: @@
 ===== History =====
-Krause is a member of the [[International Council on Harmonisation]] (ICH)'s Working Group for E8(R1) (Guideline on General Considerations for Clinical Studies).((Levenson, M., & Krause, P. (2019). //E8(R1) GENERAL CONSIDERATIONS FOR CLINICAL STUDIES.// International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. https://web.archive.org/web/20230312055636/https://qbdworks.com/storage/2019/08/Quality-by-Design-Clinical-Studies.pdf))
+Krause is a member of the [[International Council for Harmonisation]] (ICH)'s Working Group for E8(R1) (Guideline on General Considerations for Clinical Studies).((Levenson, M., & Krause, P. (2019). //E8(R1) GENERAL CONSIDERATIONS FOR CLINICAL STUDIES.// International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. https://web.archive.org/web/20230312055636/https://qbdworks.com/storage/2019/08/Quality-by-Design-Clinical-Studies.pdf)) He began his first term as a member of the Scientific Advisory Committee for the [[Coalition for Epidemic Preparedness Innovations]] (CEPI) in mid-2019.((//Summary of CEPI Scientific Advisory Committee (SAC) meeting.// (2019, February 7). European Commission. https://web.archive.org/web/20230312060536/https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5d2bd5f63&appId=PPGMS))
 ==== COVID-19 ====
@@ Line 13: / Line 13: @@
 Krause participated in a February 11-12, 2020 event titled "2019 novel Coronavirus Global research and innovation forum: towards a research roadmap" co-hosted by the [[World Health Organization]] [[R&D Blueprint]] and [[Global Research Collaboration for Infectious Disease Preparedness]] (GLOPID-R). He and [[Anuradha Poonepalli]] presented on the topic of "Candidate vaccines R&D".((//2019 novel Coronavirus Global research and innovation forum: towards a research roadmap AGENDA.// (2020). GLOPID-R. https://web.archive.org/web/20230208185417/https://www.glopid-r.org/wp-content/uploads/2020/02/covid-19-global-research-and-innovation-forum-2020-program.pdf))
-Krause was appointed Chair of the [[WHO R&D Blueprint COVID-19 Vaccines Working Group]] upon its creation in April 2020.((//WHO R&D Blueprint novel Coronavirus WHO Working Group - Target Product Profiles for COVID-19 Vaccines WHO reference number.// World Health Organization. Retrieved March 12, 2023, from https://web.archive.org/web/20230312032002/https://cdn.who.int/media/docs/default-source/blue-print/tors-working-group-on-target-product-profiles-covid19.pdf?sfvrsn=f209d4b4_1&download=true)) He participated in the 2nd Global Consultation on SARS-CoV-2 Variants of Concern and the Impact on Public Health Interventions on June 10, 2021.((//2nd Global Consultation on SARS-CoV-2 Variants of Concern and the Impact on Public Health Interventions// (p. 17). (2021). World Health Organization. https://web.archive.org/web/20230312032446/https://www.who.int/docs/default-source/coronaviruse/report-sars-global-consultation_10june2021.pdf))
+Krause was appointed Chair of the [[WHO R&D Blueprint COVID-19 Vaccines Working Group]] upon its creation in April 2020.((//WHO R&D Blueprint novel Coronavirus WHO Working Group - Target Product Profiles for COVID-19 Vaccines WHO reference number.// World Health Organization. Retrieved March 12, 2023, from https://web.archive.org/web/20230312032002/https://cdn.who.int/media/docs/default-source/blue-print/tors-working-group-on-target-product-profiles-covid19.pdf?sfvrsn=f209d4b4_1&download=true)) He participated in the [[2nd_global_consultation_on_sars-cov-2_variants_of_concern_and_their_impact_on_public_health_interventions|2nd Global Consultation on SARS-CoV-2 Variants of Concern and the Impact on Public Health Interventions]] on June 10, 2021.((//2nd Global Consultation on SARS-CoV-2 Variants of Concern and the Impact on Public Health Interventions// (p. 17). (2021). World Health Organization. https://web.archive.org/web/20230312032446/https://www.who.int/docs/default-source/coronaviruse/report-sars-global-consultation_10june2021.pdf))
+Krause began his second term on CEPI's Scientific Advisory Committee in June 2021.((//Vaccine specialists and global health experts selected for CEPI’s Scientific Advisory Committee.// (2021, June 9). CEPI. http://archive.today/2023.02.05-121837/https://cepi.net/news_cepi/vaccine-specialists-and-global-health-experts-selected-for-cepis-scientific-advisory-committee/))
 In August 2021, Krause and his superior, [[Marion Gruber]], announced they would be departing their leadership roles at the [[Food and Drug Administration]]'s Office of Vaccines Research & Review as a result of pressure from the [[Joe Biden]] White House to push ahead with [[COVID-19 vaccines|COVID-19 vaccine]] booster doses.((Weiland, N., & LaFraniere, S. (2021, August 31). //Two Top F.D.A. Vaccine Regulators Are Set to Depart During a Crucial Period.// The New York Times. https://archive.ph/gSrJj))